AOD-9604 vs Retatrutide
Overview
AOD-9604 and Retatrutide are both weight management & metabolic peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares AOD-9604 and Retatrutide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| AOD-9604 | Retatrutide | |
|---|---|---|
| Category | Weight Management & Metabolic | Weight Management & Metabolic |
| Regulatory status (US) | Research use only | Research use only |
| Typical dosage | 300 mcg | Clinical trials |
| Frequency | daily | weekly |
| Reported benefits | Fat metabolism, body composition improvement, no impact on blood sugar, cartilage repair | Enhanced weight loss beyond dual agonists, metabolic improvement |
| Reported side effects | Minimal side effects reported | Clinical trial phase |
Key differences
Primary use. AOD-9604 is categorised under Weight Management & Metabolic, while Retatrutide falls under Weight Management & Metabolic. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. AOD-9604: not FDA-approved; treated as a research compound. Retatrutide: not FDA-approved; treated as a research compound.
Dosing. AOD-9604 is typically dosed at 300 mcg (daily). Retatrutide is typically dosed at Clinical trials (weekly).
Can you stack them?
Some protocols combine peptides, but stacking AOD-9604 and Retatrutide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between AOD-9604 and Retatrutide?
- AOD-9604 and Retatrutide are both weight management & metabolic peptides, but they differ in mechanism, dosing, and regulatory status. AOD-9604 is not FDA-approved; generally classified as a research compound, whereas Retatrutide is not FDA-approved; generally classified as a research compound.
- What is AOD-9604 used for?
- Fat loss, metabolic enhancement.
- What is Retatrutide used for?
- Investigational triple agonist (GIP/GLP-1/glucagon). TRIUMPH-1 Phase 3 (May 2026): 28.3% body weight loss at 80 weeks. FDA submission anticipated Q3–Q4 2026.
- Can you take AOD-9604 and Retatrutide together?
- Some users combine peptides within a single protocol, but stacking AOD-9604 and Retatrutide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is AOD-9604 or Retatrutide FDA-approved?
- AOD-9604 is not FDA-approved; generally classified as a research compound. Retatrutide is not FDA-approved; generally classified as a research compound.
Read the full articles
- AOD-9604 — full monograph: mechanism, research, dosing & references
- Retatrutide — full monograph: mechanism, research, dosing & references